SilHF: Sildenafil in Heart Failure

Professor Andrew Clark

Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction Jan 11, 2017 - Jan 31, 2022
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection
fraction (HFrEF).
Approximately 4872 subjects will be randomized g... Read More about Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction.

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Aug 31, 2022
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.... Read More about Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - w... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study drug whic... Read More about Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.

Commander: A randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of Rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery diseas Oct 1, 2015 - May 31, 2018